Amarin (NASDAQ:AMRN – Get Free Report) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02), Zacks reports. Amarin had a negative return on equity of 7.15% and a negative net margin of 16.33%. The business had revenue of $42.30 million for the quarter, compared to the consensus estimate of $43.82 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share.
Amarin Stock Up 1.1 %
Shares of AMRN traded up $0.01 during trading hours on Friday, hitting $0.59. The company had a trading volume of 803,613 shares, compared to its average volume of 1,547,164. Amarin has a 12 month low of $0.56 and a 12 month high of $1.37. The firm has a market cap of $240.73 million, a price-to-earnings ratio of -6.51 and a beta of 1.92. The business has a fifty day moving average of $0.60 and a 200-day moving average of $0.71.
About Amarin
Recommended Stories
- Five stocks we like better than Amarin
- How is Compound Interest Calculated?
- Battle of the Retailers: Who Comes Out on Top?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What is the FTSE 100 index?
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.